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The prevalence, characteristics, expenditure and predictors of 
complementary medicine use in Australians living with 
gastrointestinal disorders: A cross-sectional study 
Abstract 
Aims: To determine the prevalence, characteristics, expenditure and predictors of complementary 
medicine (CM) use in Australian adults living with gastrointestinal disorders (GID). 
Methods: A cross-sectional study involving 2,025 Australian dults was conducted. Participants 
were recruited through purposive convenience sampling. Descriptive statistics were conducted to 
report the prevalence of people living with GIDs and their CM use, including CM products, mind-
body practices and CM practitioner services. Chi-square test and independent-samples t-test were 
used to determine the associations between sociodemographic or health-related variables with CM 
use. Binary logistic regression was conducted to deermine the significant predictors of CM use in 
GID participants. Economic data was calculated based on the mean out-of-pocket expenditure on 
CM. 
Results: Of the 293 participants reporting a GID, 186 (63.5%) used CM products, 55 (18.8%) used a 
mind-body practice and 141 (48.1%) visited at least one CM practitioner in the last 12 months. 
Collectively, the majority of GID participants using any type of CM were female, aged 40 to 49 
years, married and employed. The mean score for health-related quality of life was 49.6 out of 100 
in GID participants and 68.2 in participants without a GID (p<0.001). Average annual out-of-pocket 
expenditure on CM products was AUD127.29 by CM products users with a GID. The predictors of 
CM products, mind-body practices and CM practitioner s rvices use differed. Of the 111 CM 
product users with a GID, 103 (92.8%) disclosed all or some of their CM use to general practitioner, 
89 (80.2%) to specialist doctor, 79 (71.2%) to pharmacist and 69 (62.1%) to hospital doctor.  
Conclusions: A substantial proportion of Australian adults living with GID use CM products, mind-
body practices and CM practitioner services. This study provides important insights to inform and 
guide the development of a more coordinated health c re services for individuals living with GID.  
 



















1. Introduction  
An estimated 50-70% of Australian adults1,2 integrate complementary health approaches into 
their health care management. Complementary health approaches are broadly categorised into 
natural products, mind-body practices and may involve seeking the professional services of 
complementary medicine practitioners.3,4 The terms used to describe natural products vary around 
the world. Natural products such as herbal preparations, nutritional supplements, vitamins, minerals, 
homeopathic medicines and aromatherapy products are classified as complementary medicine (CM) 
products by the Australian Therapeutic Goods Administration.5 Mind-body practices include yoga, 
tai chi, meditation and relaxation therapy.5 Both CM products and mind-body practices are 
predominantly self-selected and used in the prevention, reatment or management of illness.3-5 In 
Australia, there is also a range of CM practitioners who provide CM health services. CM 
practitioners predominantly belong to professional associations that act as self-regulatory 
organisations.6,7 An exception to this largely self-regulated CM profession is the inclusion of 
Chinese Medicine practitioners, chiropractors and oste paths on the Australian Health Practitioner 
Regulation Agency (AHPRA).8 For the purpose of this paper, the term CM refers to CM products, 
mind-body practices and CM practitioner services.  
While it is well established that complementary approaches to health care are used by a 
substantial number of Australians,1,2 less is known about the sociodemographic and health-related 
characteristics of people living with specific conditions.2,9 Gastrointestinal disorders (GIDs) are 
common among Australian population10,11 and are broadly categorised as functional GIDs (FGIDs) 
and organic GIDs. FGIDs are the most prevalent gastrointestinal health disorders and they include 
irritable bowel syndrome (IBS), functional dyspepsia (FD) and functional constipation.10,11 The 
prevalence of organic gastrointestinal diseases has increased over the last decade,10,12 including 
gastroesophageal reflux disease (GERD), coeliac disease and inflammatory bowel diseases (IBD) 
such as Crohn’s disease (CD) and ulcerative colitis (UC).  
A recent systematic review13 that included studies conducted in the last decade reported that 
27-58% of Australian adults14-16 living with medically diagnosed GIDs used CM. The results of the 
aforementioned review13 identified that this prevalence data 14-16 were possibly no longer current 














comprehensive data on CM use by this population.13 The aims of this study were to provide current 
data on the prevalence, sociodemographic and health-related characteristics as well as out-of-pocket 
expenditure of CM use in Australian adults living with a GID. This study also aims to determine the 
predictors of CM products, mind-body practices and CM practitioner services use in this population. 
2. Methods 
2.1. Study design 
A cross-sectional online survey involving Australian dults aged 18 years or above was 
conducted. 
2.2. Settings 
The participants were recruited through purposive convenience sampling from an existing 
Australian database (Qualtrics™) of adults who had registered their interest to participate in 
research. Members of the database were invited via em il with the link to complete the online 
survey. Informed consent was obtained from the participants. A small financial incentive was 
provided to the participants in return for completing the online survey that took approximately 10 to 
15 minutes. The recruitment of participants and collection of data took approximately one month 
starting from 26th July until 28th August 2017. 
2.3. Outcome measures 
The survey questionnaire was comprised of questions related to the sociodemographic 
characteristics, health-related characteristics, CM use, conventional health service utilisation and 
communication of CM use to health care professionals (HCPs). 
2.3.1. Sociodemographic characteristics  
Participants were asked to provide their sociodemographic characteristics such as age, 
gender, postcode of residence, education level, marital status, financial manageability, employment 
and private insurance status. 
2.3.2. Health-related characteristics 
Participants were asked to indicate any diagnosed or treated chronic condition in the past 
three years from a list of 30 chronic conditions within the Australian National Health Priority Areas 
(NHPA).17 Participants were also provided with the option to indicate an ‘other health condition’ 
and specify the condition, or an option to answer ‘none of the above’ to indicate no diagnosed or 
treated chronic illness. Seven items based on the Short Form-20 (SF-20) of a medical outcomes 
study18 were used to measure the health-related quality of life (HRQOL) of participants by asking 
them to rate their health status on a 5-point Likert scale ranging from poor (1 point) to excellent (5 














health status, physical functioning, experience of b dily pain in the past four weeks, role 
functioning, mental health and current health perception. The total score of all the seven items was 
used to calculate the mean in which higher mean score reflects better CM health literacy. 
Furthermore, the 21 items of the Montana State Univers ty (MSU) Complementary and 
Alternative Medicine Health Literacy Scale (CAMHLS)19 were reviewed and modified by content 
experts for use in measuring the health literacy on herbal medicine and vitamins or mineral 
supplements among the Australian population. The scale items included five response options 
ranging from 1 (agree strongly) to 5 (disagree strongly). Twelve of the 21 items were reverse scored 
to ensure all responses were in a positive direction. Subsequently, the total score of all the 21 items 
was used to calculate the mean in which higher mean score reflects better CM health literacy. 
2.3.3. Utilisation of complementary and conventional health service and medicinal products  
Questions related to the use of CM products, mind-bo y practices and CM health services 
were developed based on the International Complementary and Alternative Medicine Questionnaire 
(I-CAM-Q),20 which has been validated in a number of population samples.20,21 I-CAM-Q requires 
country specific items that are relevant to the population study to be added into the survey 
questions.22 Therefore, the I-CAM-Q was adapted in this study for use within the cultural context of 
the Australian population. The survey participants were asked to indicate their CM use over the last 
12 months from a list of CM products, mind-body practices and CM practitioners, followed by their 
estimated out-of-pocket expenditure for each CM used.  
Furthermore, participants were asked to provide information about their conventional health 
service utilisation over the last 12 months such as the type of HCPs visited and estimated out-of-
pocket cost for each consultation. Participants were also asked to indicate if they used 
pharmaceutical medicines on a daily basis through a dichotomous (yes or no) response. If 
answering yes to this question, the participants were asked to specify the health condition that the 
medicine was taken to treat. 
2.3.4. Disclosure of CM products use to HCPs 
Participants were asked to indicate their disclosure of CM products use to conventional 
HCPs over the last 12 months by selecting one of the four response options that were “told HCPs 
about all CM use”, “told HCPs about some of the CM use”, “did not tell HCPs” and “did not visit 
this HCP”. The HCPs listed were general practitioner (GP), specialist doctor, hospital doctor and 
pharmacist.  














Data were cleaned prior to analysis using Statistical Package for the Social Science (SPSS) 
statistics version 24.23 Data were also weighed against the Australian Bureau of Statistics (ABS) 
data in year 2016 with respect to age, gender and state of residence by using a Chi-square test of 
association.24 Descriptive statistics were conducted to report the prevalence data on participants’ 
sociodemographic characteristics, health-related variables and CM use. Binary variables (yes or no) 
were created from the categorical variables that rel ted to GID and each type of CM use. For the 
purpose of analysis, participants who reported being medically diagnosed or being treated with a 
GID within the past three years will be referred to as the GID group, whilst those not reporting a 
GID will be referred to as the no-GID group. In addition, CM users were divided into CM product 
users, mind-body practice users and CM practitioner service users.  
Chi-square test of association23 was conducted to determine the statistical significance of the 
associations between categorical sociodemographic or health-related variables between the 
comparison groups. The first comparison group was GID participants versus participants without a 
GID, whereas the other comparison groups were between those CM and non-CM users in the GID 
group. Independent samples t-tests23 were conducted to compare the mean scores of HRQOL and 
CAMHLS (herbal medicine and minerals/supplements) between the comparison groups, whilst 
Levene’s test23 was used to determine the homogeneity of variance across the data. Statistical 
significance was assumed as p-value less than 0.05 (p<0.05). In addition, sociodemographic and 
health-related variables with p<0.05 or theoretical importance were included in a stepwise 
backward binary logistic regression analysis25 to determine the statistically significant predictors of 
CM products, mind-body practices and CM practitioner s rvices use in GID participants. Hosmer-
Lemeshow test26 was conducted to determine the goodness of fit for the logistic regression model. 
Economic data were calculated based on the mean out-of-pocket expenditure on each type 
of CM as well as conventional health services and medicines utilisation in participants with and 
without a GID. Subsequently, independent-samples t-tests23 were conducted to determine the 
significant difference in the mean out-of-pocket exp nditure between these two groups. Economic 
calculations of population level out-of-pocket expenditure were based on the Australian census 
figures for 2016 for Australian adults aged 20 years o  above (n=17,615,676)24 and the reported 
prevalence of GID in this study. These two figures were then multiplied to give the estimated 
number of the Australian population with a GID, which was further extrapolated from the reported 
mean expenditure by GID participants in this study to obtain the estimated total expenditure by 















This study was approved by the Human Research Ethics Committee (EC00358) at 
Endeavour College of Natural Health in accordance with the Declaration of Helsinki. 
 
3. Results 
Of the 2,025 survey respondents, six respondents’ da a with no variance were removed after 
initial screening due to the concerns of data reliability, resulting in a final 2,019 complete responses. 
The demographic profile of the participants was representative of the Australian population in terms 
of age, gender and state of residence when compared to the ABS data in year 2016 (p>0.05).24 A 
total of 1,057 (52.3%) of the 2,019 participants reported using at least one type of CM within the 
last 12 months, whilst 293 participants (14.5%) repo ted at least one medically diagnosed GID 
within the past three years. Of the 293 participants reporting a diagnosed GID, 186 (63.5%) used 
CM products, 55 (18.8%) used mind-body practices, and 141 (48.1%) visited one or more CM 
practitioners. Among the GID group (n=293), the most prevalent type of GID reported was GERD 
(44.0%), followed by IBS (35.5%), whilst the least prevalent was celiac disease (6.1%).  
3.1. Sociodemographic and health-related characteris ics of participants with and without a GID 
As presented in Table 1, participants with a GID (n=293) were predominantly female 
(69.3%), in a marital relationship (43.3%) and over 60 years of age (29.4%). Whilst the majority 
(36.9%) held an apprenticeship/certificate/diploma qu lification. Among participants with a GID, 
less than half (47.1%) were in the paid work force (versus 58.5% in no-GID group; p<0.001), whilst 
more than half (68.9%) reported financial difficulty at some or all of the time (versus 57.6% in no-
GID group; p<0.001). However, no significant difference was found in holding private health 
insurance (PHI) between participants with a GID (50.2%) and those without (51.0%; p=0.782).  
INSERT TABLE 1 HERE 
Table 2 shows that over half (57.7%) of the GID participants reported to have mental health 
disorder (versus 27.3% in no-GID group; p<0.001), whereas 38.2% had musculoskeletal disorder 
(versus 11.9% in the no-GID group, p<0.001). The mean HRQOL score in GID group was 49.60 
out of 100, which was significantly lower than the score of 68.23 in no-GID group (p<0.001). The 
mean scores of CAMHLS on herbal medicine was 3.72 out of 5 among participants with a GID 
(versus 3.59 in the no-GID group; p<0.001), whilst the mean score of CAMHLS on vitamins or 
mineral supplements was 3.74 out of 5 in GID group (versus 3.56 in the no-GID group; p<0.001) 














3.2. Sociodemographic and health-related characteris ics of CM and non-CM users with a GID 
Table 1 also summarises the results of the sociodemgraphic characteristics of CM and non-
CM users in the GID group. The use of CM was divided into three categories including CM 
products, mind-body practices and CM practitioner services. Across all three groups of CM users, 
the majority were female, aged between 40-49 years, married and employed (Table 1). The most 
common highest qualification they reported was a certificate/apprenticeship/diploma, whilst the 
least common was a year 12 qualification (Table 1). Irrespective of the CM used, more than half 
reported financial difficulty at some or all of the time. Chi-square tests of association identified 
gender, age, employment and marital status were all significantly associated with CM product use 
(p<0.05), whereas marital status and age were significa tly associated with mind-body practice use 
(p<0.05). In addition, age was the only significant factor associated with visiting a CM practitioner 
(p<0.05). 
As presented in Table 2, a significant association was identified between CM products use 
and anxiety disorder (p=0.038). GID participants who used CM products were less likely to report 
anxiety disorder (30.1%) than non-CM products users with a GID (42.1%). There was no 
significant difference between any of the three CM approaches used with the HRQOL scores 
(p>0.05). The mean score of CAMHLS on vitamins and mineral supplements was 3.68 out of 5 in 
GID participants who used CM practitioner services, which was significantly lower than that of 
non-CM practitioner service users with a GID (3.78 out of 5; p=0.024). 
3.3. Prevalence of complementary and conventional healt  services and medicinal products 
utilisation by participants with and without a GID  
As shown in Table 3, participants living with a GID were more likely to visit any of the 
conventional HCPs than those without a GID (p<0.001). The results revealed that nearly all of the 
GID participants (97.3%) had consulted a GP in the previous 12 months. Whilst the prevalence of 
consultation with community or hospital pharmacists were 89.1% in GID group (versus 74.3% in 
no-GID group; p<0.001). In relation to CM practitioner services, there were significant differences 
identified in the prevalence of consultation with massage therapists, chiropractors, acupuncturists 
and osteopaths in GID group as compared to no-GID group (p<0.05). 
Of the CM products, significant associations were id ntified between the presence of GID 
with the use of vitamins or mineral supplements, home pathy and flower essences (p<0.005) as 
presented in Table 3. Specifically, the use of vitam ns or mineral supplements was significantly 
higher in participants with a GID (61.1%) than those without a GID (45.6%; p<0.001). The 
prevalence of yoga or tai chi use was significantly lower in the GID group (7.2%) as compared to 














only and over-the-counter medicines were significantly higher in the GID group (90.8% and 78.2% 
respectively) than no-GID group (71.6% and 64.9% respectively; p<0.001).  
INSERT TABLE 3 HERE 
3.4. Out-of-pocket expenditure on complementary and conventional health services and medicinal 
product by participants with and without a GID.  
Table 4 presents the reported out-of-pocket expenditure for each health service and 
medicinal product used by the GID and no-GID groups over the last 12 months. The mean 
expenditure on CM products varied across each category and there was no significant difference for 
the mean out-of-pocket expenditure on CM products between GID and no-GID groups (p>0.05). 
Mind-body practice users with a GID had a mean expenditure on yoga or tai chi of AUD10.56 
(versus AUD37.82 in mind-body practice users withou a GID; p=0.044). Of all the health 
practitioner services, only expenditure on yoga teach rs was significantly lower in GID group 
(AUD5.40 per CM practitioner service user) compared to the no-GID group (AUD15.77 per CM 
practitioner service user; p=0.045). In addition, CM product users with a GID spent AUD197.92 
and AUD71.09 on prescription-only and over-the-counter medicines respectively, which were 
significantly higher than CM product users without a GID (AUD105.53 and AUD48.19 
respectively; p<0.005).  
Extrapolating from the available national figures24 in year 2016, and assuming an average 
individual out-of-pocket expenditure in line with tat of the GID participants from this study, the 
estimated total out-of-pocket expenditures on CM products, CM practitioner services and mind-
body practices in Australian adults aged 20 years or ab ve living with a GID (n=2,556,411) were 
approximately AUD207.7 million, AUD259.3 million and AUD16.6 million per annum 
respectively. 
INSERT TABLE 4 HERE 
3.5. Predictors of CM products, mind-body practices and CM practitioner services utilization in 
participants living with a GID 
Table 5 shows that the significant predictors of CM products use by those with a GID were 
being female and employed (p<0.05). The results also revealed that the predictors of mind-body 
practices use were being younger and having a higher education qualification (p<0.05), whilst lower 
HRQOL and younger age were the significant predictors of CM practitioner services use (p<0.05). 
The results of Hosmer-Lemeshow test indicated a good fit in the regression models for CM 














p-values were all more than 0.05. In addition, the regression model accurately classified 63% of CM 
products’ cases, 81% of mind-body practices’ cases nd 63% of CM practitioner services’ cases. 
INSERT TABLE 5 HERE 
3.6. Disclosure of CM products use to HCPs by CM product users with GID 
A total of 111 CM products users with a GID responded to the disclosure questions with 103 
(92.8%) disclosed all or some of their CM products use to their GPs, 89 (80.2%) to specialist 
doctors, 79 (71.2%) to pharmacists and 69 (62.1%) to hospital doctors (Figure 1). The most 
common reasons provided by survey participants for disclosing their CM products use (n=103) 
were that they wanted their HCPs to fully understand their health status (95.1%), they concerned 
about drug-CM interactions (83.5%), and that they trusted their HCPs would be able to help with 
their treatment decisions (74.8%). Conversely, the most common reasons provided by survey 
participants for not disclosing their CM products use (n=26) were that they were not asked by their 
HCPs (65.4%), they thought it was not important to do so (57.7%), insufficient consultation time 
with HCPs (50.0%), and that they were worried about CM use being discouraged (50.0%).  
INSERT FIGURE 1 HERE 
 
4. Discussion 
To our knowledge, this is the first study that indivi ually reports the utilisation of each CM 
approach to health care (CM products, mind-body practices, and CM practitioner services) in an 
Australian adult population living with a GID. The primary focus of this study was to report and 
critically evaluate data on CM use in participants with a GID. Meanwhile, valuable insights were 
also gained into the sociodemographic and health-reated characteristics of participants with a GID. 
4.1. Prevalence of CM use and characteristics of GID participants 
Our findings show that CM use ranged from 18.8% to 63.5% in participants with a GID, 
which was higher than those without a GID. This result is consistent with the findings of a recent 
systematic review13 that reported the use of both CM products and mind-bo y practices in 
Australian adults living with medically diagnosed GID ranged from 27% to 58%.14-16 In terms of 
sociodemographic and health-related characteristics, people living with a GID were more likely to 
be female, older in age, unemployed, reporting financial stress, have a low HRQOL and have a high 
incidence of comorbid conditions such as mental healt  nd musculoskeletal disorders. These 














The effects of these burdens may also be reflected in the higher prevalence of conventional HCPs 
consultations and pharmaceutical medicines used by this population. Together with the high 
reported out-of-pocket expenditure on conventional medicines, the impact of this cluster of 
conditions may place a substantial burden not only on the ‘public purse’ but also on these 
individuals and their household budgets. From a clinical perspective, the high concomitant use of 
both CM products and conventional medicines in the GID population raises important 
considerations about the potential risk of adverse d ug interactions. Meanwhile, the high prevalence 
of both conventional and CM practitioner consultations highlights the need for initiatives that 
facilitate the inter-professional communication betw en these health practitioners. Such initiatives 
would contribute to the integration of patients’ preferences into a more coordinated model of care 
that encourages a safer and more appropriate use of both CM and conventional medicines.  
4.2. Sociodemographic and health-related characteris ics of CM users with a GID 
The sociodemographic factors of participants with a GID who use all three types of CM 
approaches (CM products, mind-body practice and CM practitioner service) are similar to an earlier 
Australian study that identified female CM users in the general population were more likely to be 
middle-aged with a higher education and annual income compared to females who did not use CM.9 
It has been suggested that a higher education levelwas associated with a higher level of health 
literacy,27,28 better access to CM resources,27,28 greater ability for self-determination,29 and a higher 
disposable income to spend on CM.30 If these explanations apply to the participants with a GID in 
this study, it may suggest that they independently assess information and select self-determined 
health approaches to address their GI complaints. Together with the high prevalence of 
conventional medicines use in a GID population, this ‘self-selecting’ process may result in a lack of 
professional guidance about the appropriate use of CM products, thereby increasing the risk of 
adverse interactions between conventional medicines a d CM products.  
In addition, this study found that both CM product and CM practitioner service users in the 
GID group were less likely to report financial difficulties compared to those not using these two 
CM approaches. This finding may suggest that people with a GID will be more likely to use CM 
products or visit a CM practitioner for their gastrointestinal symptoms when they are more 
financially capable. The lower prevalence of anxiety disorder in CM product users with a GID does 
not align with the findings from previous studies31-33 that reported CM use was higher in individuals 
with anxiety symptoms. Given the high prevalence of reported anxiety disorder in participants with 
a GID, the beneficial effects of certain CM products in alleviating gastrointestinal symptoms may 
possibly provide a calming effect that reduces the anxiety symptoms. However, the association 















4.3. CM products use in participants with a GID  
The higher prevalence of CM products use and associated out-of-pocket expenses on CM 
products such as vitamins and mineral supplements in those with a GID compared to those without 
is also noteworthy, especially given the fact that GID participants were more likely to report 
financial difficulty than those without a GID. Furthermore, the higher prevalence of comorbidities 
and lower HRQOL in GID participants also indicate th substantial social and psychological impact 
of living with a GID. Despite this, the GID participants were still willing to carry the out-of-pocket 
expenses associated with CM products use. However, the factors that drive the use of CM products 
in people living with a GID in this study cannot be ascertained. While speculative, CM products use 
may be associated with the prevention or treatment of nutritional deficiencies due to the 
malabsorption characteristics of some GIDs.34 This speculation is based on the evidence that 
suggests those with IBD may be at an increased risk of pecific nutrient deficiencies such as iron, 
vitamins B1 and D
34-37 and those with conditions associated with diarrhoea at risk of zinc, potassium 
and magnesium depletion.38 Unlike vitamins or mineral supplements, our study revealed that both 
prevalence and expenditure of Western or Chinese herbal medicines use were lower in GID group, 
which is inconsistent with previous literature14-16 and may be related to the under-reporting by the 
survey participants. Despite the lower rates of herbal medicines use in this study, herbal medicines 
were still being used by a proportion of people living with specific types of GIDs. Such use may be 
associated with the growing body of evidence to support the use of specific herbal medicines such 
as enteric-coated peppermint oil capsules and herbal preparation STW-5 (Iberogast™) in the 
management of IBS.39,40 Given the clinical challenges with effectively managing IBS, there is a 
scope for coordinated integration of herbal medicines into the conventional care. 
4.4. CM practitioner visits in participants with a GID 
The finding that massage therapists were the most common practitioner visited may reflect 
the broader complex clinical picture that involves comorbid conditions or simply a stress reduction 
intervention. It is well known that stress is associated with the exacerbation of IBS symptoms.10,41 
The association between the brain and gastrointestial ract has emerged to have a substantial 
influence in people living with IBS.10,41 There is also some evidence to support the efficacy of 
massage techniques in managing gastrointestinal symptoms such as cramping, bloating and 
constipation.42,43 The higher prevalence of acupuncturist visits by GID participants in this study 
may be associated with the evidence to support the efficacy of specific acupuncture techniques in 
the management of IBS, constipation, diarrhoea, nause  and vomiting.44,45 Despite the prevalence of 
chiropractor and osteopath consultations was higher in GID participants, the available evidence is 
limited to support the role of chiropractic and osteopathic treatments in the management of 














musculoskeletal disorders amongst GID participants. Given the fact that people with GIDs are using 
CM practitioner services, it is important to ensure such CM practitioners are competent in their 
clinical management of GIDs and refer people with GIDs who present with ‘red flag’ signs or 
symptoms to conventional HCPs for appropriate care.   
4.5. Mind-body practices use in participants with a GID 
Our study found that the prevalence of using yoga or tai chi was lower in GID participants 
despite previous studies48-50 reported the effectiveness of such practices in allevi ting bloating and 
constipation as well as reducing stress and anxiety associated with IBS. This is possibly associated 
with the higher rate of comorbidities and lower HRQOL in GID participants that potentially affect 
their physical functioning to carry out such practices. Similarly, there was no difference identified 
in the prevalence of using relaxation or meditation therapies between GID and no-GID groups 
despite the beneficial roles of these therapies in ma aging gastrointestinal symptoms.51,52 Hence, 
further research is needed to explore the trend of using mind-body practices in GID population and 
understand the reason for their decision making in selecting such practices. 
4.6. Predictors of CM products, mind-body practices and CM practitioner services use in GID 
group 
The unique focus of this study in reporting the predictors for each CM approach use in GID 
population allows a more in-depth evaluation. The analysis identified that while GID participants 
who were female and employed had significantly increased odds of using CM products, education 
level was not a significant predictor of CM product se. Consequently, this brings earlier studies9,30 
that claimed education as one of the predictor for CM use into question, and may suggest that our 
finding is unique to the specific cohort in the population with a GID. Furthermore, it is interesting 
that younger age and higher education level were the significant predictors of mind-body practices 
use in GID participants, whereas GID participants with a lower HRQOL and younger age were 
more likely to visit a CM practitioner. The lower HRQOL in CM practitioner service users possibly 
suggests that GID participants with a lower HRQOL have unmet health needs from the 
conventional health professionals alone.  
4.7. Disclosure of CM products use to conventional HCPs 
Previous studies reported that Australians’ disclosure of CM use to conventional HCPs was 
poor with the disclosure rate ranging from 47% to 60% in year 2012.53 However, our study shows 
an encouraging result on the disclosure rate of CM products use to conventional HCPs, which 
ranged from 62.1% to 92.8% depending on the HCP consulted. This finding suggests a positive 
trend in GID patients wanting their HCPs to be aware of their CM use and monitor for any potential 
interactions between conventional and complementary medicines.54 The high CM products 














such as Australian Medical Association (AMA) in encouraging GPs to be proactive in asking 
patients about CM use.55 Furthermore, participants with a GID were less likely to disclose their CM 
products use to pharmacists than other HCPs. Given th  vast majority of CM products are sold 
through community pharmacies, the higher prevalence of non-disclosure to pharmacists remains a 
concern with the increasing reports of side effects of CM products use56-58 and other issues such as 
contamination of CM products.59 Together with the common reasons for non-disclosure identified 
in this study, it is important to ensure that pharmcists allow sufficient consultation time to engage 
in such inquiry.60 
4.8. Limitations of study 
The findings of this study should be interpreted ancontextualised within certain limitations 
related to the study design. The survey data were vulnerable to recall bias due to the reliance of self-
reporting by the participants. In particular, data such as expenditure should be treated as estimates 
of true values. The risk of recall bias was minimised by shortening the recall period specifically to 
12 months for all the conventional and complementary health services and medicinal products uses. 
The study design was subjected to sampling bias as a consequence of purposive convenience 
sampling method. In order to reduce the impact of sampling bias, the demographic profile of the 
study’s participants was compared to the ABS data24 in year 2016. To ensure the integrity of our 
data, the tools or instruments employed in the development of survey questionnaire had been 
validated in a number of population samples and they were reviewed by content experts such as CM 
practitioners, statisticians and health service researchers to ensure the cultural relevance and 
appropriateness of their use in the Australian population.18-22 
 
5. Conclusion 
A substantial proportion of people living with a GID use CM products, mind-body practices 
and CM practitioner services. The findings of this study provide an important insight into the 
sociodemographic and health-related characteristics of Australian adults living with a GID and their 
CM use. These findings can be used to guide the clinica  care provided by both conventional HCPs 
and CM practitioners to people living with GIDs. Future research is warranted to explore the use of 
specific types of CM products in people living with specific GIDs to ensure a safer and more 
coordinated health care. 
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 n % n %  n % n %  n % n %  n % n %  
Gender     <0.001*     0.032*     0.348     0.669 
Female 832 48.2 203 69.3  66 61.7 137 73.7  162 68.1 41 74.5  107 70.4 96 68.1  
Male 894 51.8 90 30.7  41 38.3 49 26.3  76 31.9 14 25.5  45 29.6 45 31.9  
Age (years)     <0.001*     0.041*     0.003*     0.001* 
18-29 468 27.1 44 15.0  18 16.8 26 14.0  30 12.6 14 25.5  18 11.8 26 18.4  
30-39 269 15.6 44 15.0  20 18.7 24 12.9  36 15.1 8 14.5  18 11.8 26 18.4  
40-49 297 17.7 65 22.2  14 13.1 51 27.4  50 21.0 15 27.3  25 16.4 40 28.4  
50-59 252 14.6 54 18.4  18 16.8 36 19.4  41 17.2 13 23.6  34 22.4 20 14.2  
60 and over 440 25.5 86 29.4  37 34.6 49 26.3  81 34.0 5 9.1  57 37.5 29 20.6  
Employment status     <0.001*     0.006*     0.239     0.075 
Full time work 572 33.1 67 22.9  25 23.4 42 22.6  50 21.0 17 30.9  28 18.4 39 27.7  
Part time work 311 18.0 59 20.1  11 10.3 48 25.8  50 21.0 9 16.4  27 17.8 32 22.7  
Casual work 127 7.4 12 4.1  2 1.9 10 5.4  8 3.4 4 7.3  5 3.3 7 5.0  
Looking for work 163 9.4 22 7.5  10 9.3 12 6.5  17 7.1 5 9.1  11 7.2 11 7.8  
Not in paid workforce 553 32.0 133 45.4  59 55.1 74 39.8  113 47.5 20 36.4  81 53.3 52 36.9  
Marital status     0.034*     0.037*     0.024*     0.542 
Never married 519 30.1 65 22.2  30 28.0 35 18.8  56 23.5 9 16.4  32 21.1 33 23.4  
Married 737 42.7 127 43.3  38 35.5 89 47.8  103 43.3 24 43.6  61 40.1 66 46.8  
De facto (Opposite sex) 183 10.6 37 12.6  13 12.1 24 12.9  28 11.8 9 16.4  23 15.1 14 9.9  
De facto (Same sex) 23 1.3 6 2.0  0 0.0 6 3.2  2 0.8 4 7.3  3 2.0 3 2.1  
Separated/divorced/widowed 264 15.3 58 19.8  26 24.3 32 17.2  49 20.6 9 16.4  33 21.7 25 17.7  
Highest qualification     0.046*     0.429     0.070     0.132 
Less than year 12 268 15.5 59 20.1  23 21.5 36 19.4  53 22.3 6 10.9  37 24.3 22 15.6  














Apprenticeship/certificate/diploma 574 33.3 108 36.9  37 34.6 71 38.2  83 34.9 25 45.5  52 34.2 56 39.7  
University degree 519 30.1 70 23.9  22 20.6 48 25.8  53 22.3 17 30.9  31 20.4 39 27.7  
Financial manageability      <0.001*     0.901     0.822     0.472 
It is difficult all of the time 343 19.9 87 29.7  34 31.8 53 28.5  69 29.0 18 32.7  51 33.6 36 25.5  
It is difficult some of the time 651 37.7 115 39.2  42 39.3 73 39.2  94 39.5 21 38.2  57 37.5 58 41.1  
It is not too bad 616 35.7 84 28.7  29 27.1 55 29.6  70 29.4 14 25.5  40 26.3 44 31.2  
It is easy 116 6.7 7 2.4  2 1.9 5 2.7  5 2.1 2 3.6  4 2.6 3 2.1  
Insurance status                     
Health care card 
a 722 41.8 117 39.9 0.542 36 33.6 81 43.5 0.096 96 40.3 21 38.2 0.769 61 40.1 56 39.7 0.942 
Private health insurance 881 51.0 147 50.2 0.782 58 54.2 89 47.8 0.295 119 50.0 28 50.9 0.903 84 55.3 63 44.7 0.070 
GID – gastrointestinal disorder, CM – complementary medicine, aHealth care cards are government cards that subsidise healthcare costs in individuals with disability 
or low socio-economic status, *Indicate a statistically significant difference between the comparison group (p<0.05). 
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 n % n %  n % n %  n % n %  n % n %  
Comorbid conditions                     
Cardiovascular disorder 337 19.5 108 36.9 <0.001* 44 41.1 64 34.4 0.251 93 39.1 15 27.3 0.102 60 39.5 48 34.0 0.336 
Diabetes-any 139 8.1 37 12.6 0.010* 16 15.0 21 11.3 0.363 29 12.2 8 14.5 0.635 18 11.8 19 13.5 0.674 
Cancer-any 108 6.3 24 8.2 0.216 9 8.4 15 8.1 0.917 20 8.4 4 7.3 0.783 12 7.9 12 8.5 0.848 
Female reproductive disorder 74 4.3 38 13.0 <0.001* 14 13.1 24 12.9 0.965 29 12.2 9 16.4 0.406 14 9.2 24 17.0 0.047 
Respiratory disorder 265 15.4 88 30.0 <0.001* 36 33.6 52 28.0 0.306 67 28.2 21 38.2 0.144 45 29.6 43 30.5 0.868 
Male reproductive disorder  35 2.0 13 4.4 0.012* 5 4.1 8 4.3 0.882 12 5.0 1 1.8 0.295 6 3.9 7 5.0 0.673 
Mental health disorder 472 27.3 169 57.7 <0.001* 69 64.5 100 53.8 0.074 133 55.9 36 65.5 0.195 84 55.3 85 60.3 0.385 
Musculoskeletal disorder 205 11.9 112 38.2 <0.001* 39 36.4 73 39.2 0.635 91 38.2 21 38.2 0.994 58 38.2 54 38.3 0.980 
Other chronic illness 122 7.1 26 8.9 0.273 7 6.5 19 10.2 0.287 20 8.4 6 10.9 0.556 11 7.2 15 10.6 0.306 
Specific GIDs                     














Inflammatory bowel disease n.a. n.a. 22 7.5 n.a. 7 6.5 15 8.1 0.634 16 6.7 6 10.9 0.288 14 9.2 8 5.7 0.251 
Celiac disease n.a. n.a. 18 6.1 n.a. 5 4.7 13 7.0 0.427 13 5.5 5 9.1 0.312 9 5.9 9 6.4 0.869 
Gastroesophageal reflux disease n.a. n.a. 129 44.0 n.a. 47 43.9 82 44.1 0.979 107 45.0 22 40.0 0.504 72 47.4 57 40.4 0.232 
Chronic constipation n.a. n.a. 47 16.0 n.a. 16 15.0 31 16.7 0.700 38 16.0 9 16.4 0.942 23 15.1 24 17.0 0.660 
Other GID n.a. n.a. 62 21.2 n.a. 18 16.8 44 23.7 0.168 46 19.3 16 29.1 0.110 27 17.8 35 24.8 0.139 
Specific comorbid conditions                     
Hypertension 277 16.0 81 27.6 <0.001* 37 34.6 44 23.7 0.044* 72 30.3 9 16.4 0.038* 44 28.9 37 26.2 0.605 
Osteoarthritis 149 8.6 69 23.5 <0.001* 27 25.2 42 22.6 0.606 60 25.2 9 16.4 0.163 41 27.0 28 19.9 0.152 
Other musculoskeletal disorders 87 5.0 65 22.2 <0.001* 18 16.8 47 25.3 0.094 48 20.2 17 30.9 0.084 28 18.4 37 26.2 0.107 
Asthma 180 10.4 61 20.8 <0.001* 26 24.3 35 18.8 0.266 46 19.3 15 27.3 0.191 32 21.1 29 20.6 0.919 
Bronchitis  57 3.3 24 8.2 <0.001* 11 10.3 13 7.0 0.323 18 7.6 6 10.9 0.415 14 9.2 10 7.1 0.509 
Other respiratory disorders 70 4.1 28 9.6 <0.001* 10 9.3 18 9.7 0.926 23 9.7 5 9.1 0.896 13 8.6 15 10.6 0.544 
Mood disorder 274 15.9 113 38.6 <0.001* 48 44.9 65 34.9 0.093 89 37.4 24 43.6 0.391 55 36.2 58 41.1 0.384 
Anxiety 301 17.4 101 34.5 <0.001* 45 42.1 56 30.1 0.038* 81 34.0 20 36.4 0.743 49 32.2 52 36.9 0.403 
Sleep disorder 181 10.5 84 28.7 <0.001* 30 28.0 54 29.0 0.856 67 28.2 17 30.9 0.684 38 25.0 46 32.6 0.149 
Substance abuse 41 2.4 14 4.8 0.019* 5 4.7 9 4.8 0.949 9 3.8 5 9.1 0.096 6 3.9 8 5.7 0.489 
Health related quality of life MS SD MS  SD P-value MS SD MS  SD P-value MS SD MS  SD P-value MS SD MS  SD P-value 
General health status 54.8 26.3 36.8 26.6 <0.001* 36.0  25.3 37.2 27.4 0.693 36.7 26.1 37.3 28.8 0.855 36.5 25.1 37.1 28.3 0.862 
Physical functioning  76.9 28.8 55.6 34.1 <0.001* 55.8  34.2 55.4 34.2 0.919 55.6 35.1 55.5 29.9 0.977 58.2 34.8 52.8 33.3 0.176 
Bodily pain (Past 4 weeks) 67.1 24.6 49.2 26.0 <0.001* 48.0  24.7 49.9 26.8 0.549 48.2 25.5 53.8 28.0 0.173 51.2 5.8 47.1 26.2 0.180 
Role functioning 76.0 37.1 48.0 42.1 <0.001* 47.9  42.2 48.1 42.1 0.966 47.8 42.4 49.1 41.1 0.834 49.7 43.2 46.3 41.0 0.490 
Social functioning  78.9 28.4 63.0 31.0 <0.001* 63.7   30.7 62.6 31.2 0.758 64.6 30.8 56.0 31.1 0.067 67.2 30.8 58.4 30.5 0.015* 
Mental health 65.0 22.8 55.4 22.1 <0.001* 54.0 23.1 56.2 21.5 0.425 55.9 23.1 53.2 17.2 0.412 57.5 23.9 53.1 19.9 0.081 
Current health perception 59.0 25.4 39.2 25.3 <0.001* 37.9 25.5 40.0 25.3 0.502 39.0 25.5 40.1 24.8 0.773 40.6 26.0 37.7 24.7 0.324 
Mean HRQOL 68.2 20.8 49.6 22.9 <0.001* 49.1 22.4 49.9 23.2 0.755 49.7 23.2 49.3 21.5 0.902 51.6 23.3 47.5 22.3 0.127 
Complementary and alternative 
medicine health literacy scale 
MS SD MS  SD P-value MS SD MS  SD P-value MS SD MS  SD P-value MS SD MS  SD P-value 
Herbal medicine 3.59 0.41 3.72 0.42 <0.001* 3.69 0.49 3.73 0.37 0.462 3.70 0.41 3.77 0.42 0.252 3.76 0.44 3.67 0.38 0.072 
Vitamin/supplements 3.56 0.40 3.74 0.38 <0.001* 3.72 0.43 3.74 0.35 0.682 3.74 0.38 3.73 0.36 0.889 3.78 0.40 3.68 0.35 0.024* 
GID – gastrointestinal disorder, CM – complementary medicine, n.a. – not applicable, MS – mean score, SD – standard deviation, *Indicate a statistically significant 















Prevalence of conventional and complementary health services and products utilisation by GID 
(n=293) and no-GID (n=1,726) participants in the last 12 months. 












n % n   % 
Medical doctor   
General practitioner* 285 97.3 1471 85.2 <0.001 
Specialist doctor* 200 68.3 639 37.0 <0.001 
Hospital doctor* 127 43.3 441 25.6 <0.001 
Allied health    
Pharmacist* 261 89.1 1283 74.3 <0.001 
Physiotherapist* 86 29.4 349 20.2 <0.001 
Counsellor/psychologist* 87 29.7 331 19.2 <0.001 
Community nurse* 50 17.1 154 8.9 <0.001 
Pharmaceuticals    
Prescription-only* 266 90.8 1236 71.6 <0.001 
Over-the-counter* 229 78.2 1120 64.9 <0.001 












n % n % 
CM practitioner      
Massage therapist* 79 27.0 339 19.6 0.004 
Chiropractor* 52 17.7 202 11.7 0.004 
Yoga teacher 22 7.5 158 9.2 0.361 
Acupuncturist* 32 10.9 127 7.4 0.036 
Naturopath 21 7.2 105 6.1 0.478 
Osteopath* 28 9.6 82 4.8 0.001 
TCM practitioner 12 4.1 95 5.5 0.320 
Aromatherapist 13 4.4 66 3.8 0.617 
Homeopath 7 2.4 61 3.5 0.315 
CM products      
Vitamins/mineral supplements* 179 61.1 787 45.6 <0.001 
Aromatherapy oils 33 11.3 191 11.1 0.921 
Western/Chinese herbal medicine 19 6.5 172 10.0 0.060 
Homeopathy* 9 3.1 129 7.5 0.006 
Flower essences* 13 4.4 138 8.0 0.032 
Mind-body practice      
Yoga/tai chi* 21 7.2 216 12.5 0.009 














GID – gastrointestinal disorder, CM – complementary medicine, *Indicates a statistical significant difference 



















Type of medicinal products 
 










expense in no-GID 
participants (AUD) 
 
Mean annual expense 










Per CM product user 
(n=830) 
Per CM product user 
(n=186) 
Pharmaceuticals    
Prescription-only* 206,761.69 52,721.49 459,992,481.13 105.53 197.92 0.001 
Over-the-counter* 79,798.05 17,454.00 152,285,316.02 48.19 71.09 0.015 
Total  286,559.74 70,175.49 612,277,797.15 153.72 269.01  
CM products          
Vitamins/mineral supplements 88,297.20 18,849.00 164,456,624.37 83.29 100.61 0.278 
Aromatherapy oils 10,381.00 2,913.00 25,415,785.81 8.90 15.66 0.064 
Western/Chinese herbal medicine 11,534.00 1,365.00 11,909,559.78 12.12 7.34 0.094 
Homeopathy 7,239.00 303.00 2,643,660.52 8.26 1.63 0.146 
Flower essences 5,107.00 380.00 3,315,481.84 5.58 2.05 0.062 
Total 122,558.20 23,810.00 207,741,112.32 118.15 127.29  
 
 
Type of healthcare professionals 
 










expense in no-GID 
participants (AUD) 
 
Mean annual expense 











Per CM practitioner 
service user (n=585) 
Per CM practitioner 
service user (n=141) 
Conventional health practitioner        
General practitioner 263,224.06 17,912.00 156,281,344.14 351.02 103.21 0.188 
Specialist doctor 243,453.05 39,786.00 347,130,948.96 205.31 187.76 0.871 














Pharmacist n.a. n.a. n.a. n.a. n.a. n.a. 
Community nurse 7,185.00 890.00 7,765,207.47 10.38 5.04 0.155 
Physiotherapist 39,963.37 6,518.00 56,869,238.56 41.85 33.70 0.434 
Counsellor/psychologist 53,556.00 6,475.00 56,494,065.61 42.35 33.72 0.457 
Total 679,881.48 78,020.00 680,720,772.08 709.87 395.24  
CM practitioner  
Massage therapist 40,961.00 8,044.00 70,183,515.65 56.36 57.05 0.959 
Chiropractor 32,738.00 7,209.00 62,898,180.54 43.64 51.13 0.637 
Yoga teacher* 9,990.00 762.00 6,648,413.59 15.77 5.40 0.045 
Acupuncturist 14,492.00 2,420.00 21,114,384.37 20.71 17.16 0.588 
Naturopath 15,708.00 3,878.00 33,835,364.70 20.22 27.50 0.518 
Osteopath 9,833.00 1,860.00 16,228,411.13 13.63 13.19 0.910 
TCM practitioner 9,147.00 1,179.00 10,286,718.67 13.62 8.36 0.241 
Aromatherapist 11,881.00 1,553.00 13,549,850.80 17.65 11.01 0.501 
Homeopath 7,892.00 1,385.00 12,084,058.82 11.12 9.82 0.869 
Western herbalist 7,545.00 1,425.00 12,433,056.91 10.48 10.11 0.961 
Total 160,187.00 29,715.00 259,261,955.17 223.20 210.73  
 
 
Type of mind-body practices 
 










expense in no-GID 
participants (AUD) 
 
Mean annual expense 












practice user (n=322) 
Per mind-body 
practice user (n=55) 
Yoga/tai chi* 13,138.00 581.00 5,069,197.24 37.82 10.56 0.044 
Relaxation/meditation 10,491.00 1,316.00 11,482,037.12 26.80 23.78 0.804 
Total  23,629.00 1,897.00 16,551,234.36 64.62 34.34  
GID – gastrointestinal disorder, CM – complementary medicine, aThe estimated number of Australian population with a GID (n=2,556,411) was calculated based on 
Australian census figures in year 2016 for Australian adults aged 20 years or above (n=17,615,676) and the reported prevalence of GID in this study (14.5%), 
*Indicates a significant difference between GID and no-GID groups (p<0.05), n.a. – not applicable as pharmacist consultation is usually free of charge, TCM – 








































CM products use 
 
Mind-body practices use 
 
CM practitioner services use 
 
OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value 
Gender  
(0=female, 1=male)          
0.50 0.29-0.87 0.014* 0.89 0.43-1.85 0.758 1.28 0.73-2.25 0.381 
Age  
(Low to high) 
1.17 0.95-1.44 0.141 0.69 0.53-0.89 0.004* 0.74 0.60- .91 0.005* 
Financial manageability  
(Difficult to easy) 
1.09 0.78-1.51 0.624 0.95 0.63-1.42 0.791 1.34 0.93-1 86 0.082 
Employment status 
(Employed to unemployed) 
0.81 0.67-0.97 0.024* 1.01 0.81-1.26 0.930 0.86 0.71-1.03 0.097 
Education level 
(Low to high) 
1.06 0.82-1.38 0.639 1.44 1.01-2.03 0.041* 1.12 0.87-1.45 0.380 
Marital status  
(No to in-relationship) 
0.98 0.81-1.19 0.850 1.23 0.96-1.56 0.097 1.02 0.84-1 23 0.882 
Private insurance  
(0=no, 1=yes) 
0.87 0.51-1.49 0.616 1.05 0.53-2.06 0.900 0.62 0.36-1 05 0.077 
Health care card  
(0=no, 1=yes) 
1.13 0.63-2.01 0.685 0.93 0.45-1.91 0.834 0.79 0.44-1 0 0.416 
Health-related quality of life  
(Low to high) 
1.00 0.98-1.01 0.389 1.00 0.98-1.01 0.670 0.98 0.97- 9 0.001* 























































































Type of health care professionals
Disclosure of CM products use to health care professionals by GID 
participants who used CM products
Disclosed all CM products use
Disclosed some CM products use
Not disclosed
Not visited
CM – complementary medicine, GID – gastrointestinal disorder. 
